Pathologic response after neoadjuvant chemoradiotherapy in Sudanese patients with locally advanced rectal adenocarcinoma

  • Authors

    • Ahmed Abdalla University of Gezira
    • Awad Alawad University of Medical Sciences and Technology
    • Hussein Abdalla M. Ali
    2015-06-25
    https://doi.org/10.14419/ijm.v3i2.4836
  • Neoadjuvant, Rectal Cancer, Chemoradiation, Pathological Response.
  • Background: Locally advanced rectal cancer can be down staged by neoadjuvant therapy and the resultant tumor response can be quantified histologically.

    Objective: This study aimed to assess pathologic response of neoadjuvant chemoradiation in patients with locally advanced rectal cancers treated in Wad Medani Teaching Hospital (WMTH) and National Cancer Institute (NCI), Wad Medani, Sudan.

    Patients and Methods: A total of 36 consecutive patients with locally advanced rectal cancer that were managed in WMTH and NCI during the period from 2006-2011 were reviewed. Preoperative pelvic radiotherapy was delivered.  The total of 46 Grays were delivered concurrently with 5- fluorouracil (5-FU) on the first and last week of radiation. Total mesorectal excision of the rectal tumour either by anterior or abdominoperineal resections was planned at 6-8 weeks from completion of preoperative treatment. The pathological response to therapy was assessed by histopathology examination of the surgical specimen.

    Results: Initial clinical staging of patients revealed 58.3% of them were stage T3/T4N2M0 and 41.7% were stage T3N0M0. Down-staging to stage T1/T2N0M0 was found in 36.1% and stages T3N0M0 in 30.6%. No response was seen in 8.3% of cases with stage T3/T4N2M0 while a complete clinical response (no residual) was seen in 25.0%. Complete histological response was observed 13.8%. Positive lymph-nodes metastasis was confirmed in 8.3% of cases.

    Conclusion: Neoadjuvant chemoradiation is a reasonable option for cases of rectal cancer and deserves further evaluation.

  • References

    1. [1] Elrahman AAEAA, Alshaihk AA, Abuidris D & Elfatih M (2012): Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes for patients treated in Wad Medani Teaching Hospital and National Cancer Institute (Sudan) in the period 2006-2011. Sudan Medical Journal 48, 129-134.

      [2] Bujko K, Michalski W, Kepka L, Nowacki MP, Nasierowska-Guttmejer A, Tokar P, Dymecki D, Pawlak M, Lesniak T, Richter P, Wojnar A, Chmielik E & Polish Colorectal Study G (2007): Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67, 369-377.http://dx.doi.org/10.1016/j.ijrobp.2006.08.065.

      [3] Chao JY, Wang HM, Chiang FF, Lin JC, Chang CF, Lin JF & Yeh HL (2014): Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan. J Chin Med Assoc 77, 128-132.http://dx.doi.org/10.1016/j.jcma.2013.11.008.

      [4] Choi CH, Kim WD, Lee SJ & Park WY (2012): Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer. Radiat Oncol J 30, 99-107.http://dx.doi.org/10.3857/roj.2012.30.3.99.

      [5] Ciccocioppo A, Stephens JH, Hewett PJ & Rieger NA (2009): Complete pathologic response after preoperative rectal cancer chemoradiotherapy. ANZ J Surg 79, 481-484.http://dx.doi.org/10.1111/j.1445-2197.2009.04950.x.

      [6] Garland ML, Vather R, Bunkley N, Pearse M & Bissett IP (2014): Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis 29, 301-307.http://dx.doi.org/10.1007/s00384-013-1821-7.

      [7] Maretto I, Pomerri F, Pucciarelli S, Mescoli C, Belluco E, Burzi S, Rugge M, Muzzio PC & Nitti D (2007): The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol 14, 455-461.http://dx.doi.org/10.1245/s10434-006-9269-4.

      [8] Sun Y, Chi P, Xu B, Lin H, Lu X, Huang Y, Xu Z, Huang S & Jiang C (2014): [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 17, 556-560.

      [9] Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Kamijo A, Akiba T & Kawada S (2014): Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. J Surg Oncol 109, 659-664.http://dx.doi.org/10.1002/jso.23550.

      [10] Yoon SM, Kim DY, Kim TH, Jung KH, Chang HJ, Koom WS, Lim SB, Choi HS, Jeong SY & Park JG (2007): Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 69, 1167-1172.http://dx.doi.org/10.1016/j.ijrobp.2007.04.047.

      [11] Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ & Kim HR (2015): Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. Ann Surg Treat Res 88, 15-20.http://dx.doi.org/10.4174/astr.2015.88.1.15.

  • Downloads

  • How to Cite

    Abdalla, A., Alawad, A., & Abdalla M. Ali, H. (2015). Pathologic response after neoadjuvant chemoradiotherapy in Sudanese patients with locally advanced rectal adenocarcinoma. International Journal of Medicine, 3(2), 53-55. https://doi.org/10.14419/ijm.v3i2.4836